

Corrigendum

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

Patrizia Mondello, Elliott J. Brea, Elisa De Stanchina, Eneda Toska, Aaron Y. Chang, Myles Fennell, Venkatraman Seshan, Ralph Garippa, David A. Scheinberg, José Baselga, Hans-Guido Wendel, and Anas Younes

Original citation: JCI Insight. 2017;2(6):1–14. <https://doi.org/10.1172/jci.insight.90196>.

Citation for this corrigendum: JCI Insight. 2018;3(22):e125568. <https://doi.org/10.1172/jci.insight.125568>.

David A. Scheinberg's conflict-of-interest statement was not included in the manuscript. The correct statement is below.

DAS sits on boards for, was a consultant to, and/or owns stock or options in Sellas Life Sciences, Progenics Pharmaceuticals, Actinium Pharmaceuticals Inc., and Great Point Partners, companies that are not germane to the work in this paper. DAS owned stock in the following companies: Johnson & Johnson, Pfizer, and Abbott as well as DaVita, Intuitive Surgical, Edwards Lifesciences, Sapience Therapeutics, and ContraFect Corp.; these latter companies are not related to the work in this paper. DAS is an inventor on patents (US patent nos. 10,040,865, 9,976,137, 9,919,037, 9,289,519, 8,486,409, 6,156,316, 5,730,982, 6,603,127, 7,488,718, and 7,747,395) owned by Memorial Sloan Kettering Cancer Center and not germane to the work in this paper.

The authors regret the error.